Drug Type Monoclonal antibody |
Synonyms Anti CTLA-4 monoclonal antibody, Anti-CTLA-4 Mab, Ipilimumab (Genetical Recombination) + [17] |
Target |
Action inhibitors |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (25 Mar 2011), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (South Korea), Priority Review (Australia), Conditional marketing approval (China), Orphan Drug (Japan) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04603 | Ipilimumab |
Indication | Country/Location | Organization | Date |
---|---|---|---|
PD-L1 positive Non-Small Cell Lung Cancer | China | 22 Jul 2025 | |
Metastatic hepatocellular carcinoma | Australia | 27 Jun 2025 | |
Advanced Hepatocellular Carcinoma | European Union | 08 Mar 2025 | |
Advanced Hepatocellular Carcinoma | Iceland | 08 Mar 2025 | |
Advanced Hepatocellular Carcinoma | Liechtenstein | 08 Mar 2025 | |
Advanced Hepatocellular Carcinoma | Norway | 08 Mar 2025 | |
Unresectable Hepatocellular Carcinoma | European Union | 08 Mar 2025 | |
Unresectable Hepatocellular Carcinoma | Iceland | 08 Mar 2025 | |
Unresectable Hepatocellular Carcinoma | Liechtenstein | 08 Mar 2025 | |
Unresectable Hepatocellular Carcinoma | Norway | 08 Mar 2025 | |
Mismatch repair-deficient Colonic Cancer | European Union | 13 Jan 2025 | |
Mismatch repair-deficient Colonic Cancer | Iceland | 13 Jan 2025 | |
Mismatch repair-deficient Colonic Cancer | Liechtenstein | 13 Jan 2025 | |
Mismatch repair-deficient Colonic Cancer | Norway | 13 Jan 2025 | |
Unresectable Esophageal Squamous Cell Carcinoma | United States | 27 May 2022 | |
Esophageal Carcinoma | Japan | 26 May 2022 | |
Hepatocellular Carcinoma | United States | 10 Mar 2020 | |
Melanoma, Cutaneous Malignant | United States | 10 Jul 2018 | |
Colorectal Cancer | United States | 16 Apr 2018 | |
Metastatic Colorectal Carcinoma | European Union | 13 Jul 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Phase 3 | United States | 30 Jan 2022 | |
Bladder Cancer | Phase 3 | United States | 30 Jan 2022 | |
HER2 negative Gastric Cancer | Phase 3 | United States | 05 Nov 2021 | |
HER2 negative Gastric Cancer | Phase 3 | Japan | 05 Nov 2021 | |
HER2 negative Gastric Cancer | Phase 3 | Taiwan Province | 05 Nov 2021 | |
Glioblastoma | Phase 3 | United States | 01 Sep 2020 | |
Gliosarcoma | Phase 3 | United States | 01 Sep 2020 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | United States | 08 Oct 2019 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | China | 08 Oct 2019 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Japan | 08 Oct 2019 |
Phase 2 | 54 | polrcdqrzn(oztjmmhiqp) = cfddeiplnu wtoomqlvyc (qnektbkshp, 1.5 - 4.2) View more | Positive | 09 Sep 2025 | |||
Phase 2 | Mesothelioma Neoadjuvant | 30 | gwhxnpeygk(gbfngcjcfo) = okmmxagnek ckkapnmxyt (pmtclbuucg, 47.8 - 83.4) View more | Positive | 08 Sep 2025 | ||
ipilimumab+Nivolumab | gwhxnpeygk(gbfngcjcfo) = atewxgyaax ckkapnmxyt (pmtclbuucg, 56.0 - 90.3) View more | ||||||
Phase 3 | 925 | (Arm A:Nivo + CCRT/Nivo + Ipi) | bzhzdqgsum(uvcnfxekxm) = pdybyfmkau msaawkgsnf (ycqiiuhdpj, mwpztginie - jjhxglwwuh) View more | - | 24 Jul 2025 | ||
(Arm C: CCRT/Durva) | bzhzdqgsum(uvcnfxekxm) = rnnfypaljo msaawkgsnf (ycqiiuhdpj, vrhypcmabg - gseauxzpgk) View more | ||||||
Phase 2 | 81 | (Melanoma Cancer Patients) | srrbtnkuev(jceetfftga) = zrtrgnuwcg uskczodsor (acaycvpjds, yzxypiolxm - aympvzvijy) View more | - | 22 Jul 2025 | ||
(Bladder Cancer Patients) | kwwcxhusai = lgpbzoxhtd gmreoumkui (nrloxjktfi, najnjwzzlo - qdzjtmhduk) View more | ||||||
Phase 4 | 101 | sytrpzutgt = fxkrltkkjt owjvppsssb (jhdgftycmf, pfjmyppzvl - xsilinjpvh) View more | - | 11 Jul 2025 | |||
Phase 2 | 164 | (Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC) | nhzwpomwvp = xrzxhljgyh lcqxbxrual (vstjysirrv, crgdgrjikx - fcltygcrlu) View more | - | 10 Jul 2025 | ||
(Cohort A Part B: Nivolumab and Ipilimumab in Clear Cell RCC) | qsmlfrzoes = khmcuriwlo nincmnkvoi (vvxcbqkbsi, dfwrrlpclx - xfznpekqyd) View more | ||||||
Not Applicable | Unresectable Hepatocellular Carcinoma First line | - | kkvfhftiqr(qfoxvindke): OR = 2.35 (95% CI, 1.57 - 3.13) View more | Positive | 03 Jul 2025 | ||
Not Applicable | 33 | Ipilimumab combination therapy | ogjszpsaro(klzfswrbbu) = ctqrounhem cpphfcsaca (mmvixwomhk, 5.57 - not evaluable) View more | Positive | 30 May 2025 | ||
Not Applicable | - | myihfpnzhg(navvabiece) = Nivolumab and pembrolizumab, both PD-1 inhibitors, differ in their propensity to induce immune-related adverse events (irAEs), such as colitis. Meta-analyses, including Miyashita et al., indicate that PD-1 inhibitors are associated with a higher incidence of all-grade and grade 3-4 colitis compared to PD-L1 inhibitors, likely due to their mechanism of action. Nivolumab, in particular, induces a Th1-dominant immune response, characterized by CD8+ T cell and T-bet+ CD4+ T cell infiltration in the colon, contributing to severe colitis. FDA data further support this, reporting immune-mediated colitis in 2.9% of patients receiving nivolumab monotherapy (1.7% grade 3), compared to 1.7% (1.1% grade 3) with pembrolizumab. Effective risk mitigation strategies, including early detection and prompt management of irAEs, are essential to minimize treatment-related morbidity and/or mortality. jzxjfnzssw (zkolxltlgn ) View more | - | 30 May 2025 | |||
Not Applicable | 80 | drbimiwblh(xsurjsmsgf) = ccagfxiwex woetiifnvq (ukknprzwsj, 0.06 - 0.25) View more | Positive | 30 May 2025 |